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Abstract
Introduction. Multiple myeloma is a hemathological malig-
nancy characterized by the clonal proliferation of plasma
cells in the bone the marrow. Extramedullary dissemination
of multiple myeloma is uncommon. In several cases only,
the multiple myeloma malignant plasma cells had disemi-
nated to the lung parenchyma. Case report. We presented a
case of multiple myeloma with lung plasmacytoma, in a 79-
year-old patient, hospitalized for febrility and infiltrative
mass in the right lung. Two months before the patient was
admitted, because of developing terminal renal failure, he-
modialysis treatment had started three times a week. Since
then, the patient was oliguric, but because of febrility and
hemoptysis that appeared, at first he was treated with dual
antibiotic therapy which resulted in temporary improvement
of his general condition, but pleural effusion remained. Af-
ter thoracocentesis, followed by myelogram, the multiple
myeloma diagnosis was established. Conclusion. In pa-
tients of middle and older age, with general weakness, ex-
haustion, loss of weight, renal failure which progresses to
the end stage rapidly, if symptoms of respiratory tract occur,
consider this uncommon disease – extramedullary dissemi-
nation of multiple myeloma.
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Apstrakt
Uvod. Multipli mijelom je hematološko maligno oboljenje
koje se odlikuje klonalnom proliferacijom plazma ýelija u
koštanu srž. Ekstramedularna diseminacija multiplog mije-
loma izuzetno je retka. U samo nekoliko sluÿajeva opisana je
diseminacija multiplog mijeloma u pluýa. Prikaz bolesnika.
Prikazali smo bolesnika sa multiplim mijelomom pluýne lo-
kalizacije, starog 79 godina, koji je hospitalizovan zbog feb-
rilnosti i infiltrativne promene u desnom pluýu. Dva meseca
pre prijema, zbog razvoja terminalne bubrežne slabosti, za-
poÿeto je leÿenje hemodijalizom, tri puta nedeljno. Od tog
perioda bolesnik je bio oliguriÿan, a zbog pojave febrilnosti i
hemoptizija leÿen je najpre dvojnom antibiotskom terapi-
jom, na ÿiju primenu je došlo do prolaznog poboljšanja op-
šteg stanja, ali bez povlaÿenja pleuranog izliva. Nakon uÿi-
njene torakocenteze, a potom i mijelograma, postavljena je
dijagnoza multiplog mijeloma. Zakljuÿak. Kod bolesnika
srednjeg i starijeg životnog doba uz opštu slabost, malaksa-
lost, gubitak telesne mase, bubrežnu insuficijenciju koja br-
zo progredira do terminalne, ukoliko se pojave simptomi u
respiratornom traktu, diferencijalno dijagnostiÿki treba raz-
mišljati i o ekstramedularnoj, pluýnoj diseminaciji multiplog
mijeloma.
Kljuÿne reÿi:
multipli mijelom; neoplazme, diseminacija; pluýa;
plazma ýelije.
Introduction
Multiple myeloma (MM) is a plasmaproliferative dis-
ease that is most often characterized with uncontrolled
monoclonal proliferation of plasma cells in the bone marrow.
As a consequence of tumor activity and its products, there
are osteolytic lesions, osteopenia with pathologic fractures,
followed with hypercalcemia, renal failure and hyperviscous
syndrome 
1, 2. It appears in adults, more often male, the aver-
age age around 65 years and constitutes approximately 1% of
all malignant diseases and slightly more than 10% of all he-
matologic malignancies 
3–5. The annual incidence in America
is approximately 4í5 in 100,000 people and the similar trend
is recorded in Europe, too 
5–7.
Extramedullary plasmacytoma (EMP) represents ap-
proximately 3% of plasma cell neoplasms. EMP are uncom-
mon and typically manifested like solitary plasmocytoma,
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5% of all extramedullary plasmocitomas is localized in-
trapulmonary 
8.
 Having in mind rates of occurrences of the
abovesaid diseases, MM with pulmonary localization is con-
sidered as very uncommon.
Renal failure appears in this disease in approximately
50% of patients and is manifested as chronic, but rarely as
acute renal failure. Whereas, it is a well-known fact that
myeloma spreading to kidneys is an adverse prognostic
sign
 9, 10.
Chejfec et al. 
11 defined even in 1983 the term “mye-
loma lung” with diffuse infiltrative plasma cells in pleural
punctate or tissue samples obtained with needle biopsy and
in rarely described cases, with MM spreading to lungs. The
diagnosis is often established with biopsy, intraoperatively or
by autopsy 
11, 12.
Case report
A 79-year old male patient was admitted to our depart-
ment as a dialysis patient with temporary vascular access
(CVC-right jugular vein), pronounced anemic syndrome,
febrility and infiltrative mass in the right lung. Regular he-
modialysis, three times a week lasting 4 hours, had started 2
months before he was hospitalized in our hospital, but addi-
tional difficulties had occurred 4 weeks before he was ad-
mitted with body temperature of up to 40°C. He was hospi-
talized in a regional hospital on suspicion of pleuropneumo-
nia, and dual antibiotic therapy was introduced. This therapy
led to lowering body temperature, but the increased levels of
acute infection phase reactants remained with sedimentation
rate 84 mm/h and C-reactive protein 103 mg/L. According to
objective findings, the patient was markedly pale, with visi-
ble mucosa and with weakened respiratory murmur in the
right lung, with a mass of inspirium crackles and inaudible
breathing on the basis, left lung. The radiography of the
lungs showed the infiltrative mass in the right lung with the
presence of pleural effusion in both, more in the left (Figure
1), while the bronchoscopic findings were normal. The ultra-
sound of abdomen was almost normal, except the left kidney
which was with a larger number of cysts, and the largest one
was around 45 mm.
Fig. 1 í Infiltrative mass in the right lung, and the presence
of pleural effusion in the left one.
Computed tomography (CT) of the chest confirmed the
existing pleural effusion in both lungs and in the right, the
zones that would most likely correspond to pneumonitis.
Additionally, at the level of the thoracic vertebral body Th9-
Th10, there was a hyperdense, solid mass with the diameter
of 32 u 19.5 mm, while the other was with the diameter of up
to 18 mm at the level of transversal L4 (Figure 2). Osteolytic
changes were not observed.
Fig. 2 í Magnetic resonance imaging – a paravertebral
tumor mass.
Magnetic resonance imaging (MRI) of the thoracic and
lumbar spine confirmed the existence of paravertebral tumor
mass on both sides, without any sign of bone destruction.
Laboratory analyses showed anemic syndrome which
required substitution (red blood cells 2.87 í 3.33 u 10¹²,
hemoglobin 83í101 g/L, hematocrit 0.26í0.29), while the
differential blood test found monocytosis (16í17.3% Mo)
with white blood cells 14.9í9.31 u 10
9. The values of urea
and serum creatinine were such that the patient was on
regular hemodialysis program three times a week (creatin-
ine around 700 μmol/L and urea 20 mmol/L; creatinine
clearance rate was of around 6 mL/min). The patient was
anuric. The values of alkaline phosphatase ranged from
317í838í407 IU/L, lactate dehydrogenase 914í843 IU/L
and once serum hypercalcemia was recorded to be up to
2.71 mg/dL, while the values of total proteins were from
75í87 g/L with normal and slightly lower albumins (35í31
g/L). The completed serum protein electrophoresis indi-
cated M-peak in gamma globulins (36.2%), albumins
44.1%, Į1 globulins 4.9%, Į2 globulins 7.8%, ȕ1 globulins
2.4%,  ȕ2 globulins 4.6%. Immunoglobulin (Ig) Ȝ light
chains were 11.8%, and ț light chains 2.49%. The ratio ț/Ȝ
was 0.21. Because of the aforementioned pleural effusion,
thoracocentesis was done, but the cytological findings of
pleural punctuate corroborated plasmacytic infiltration
(Figure 3), while in myelogram done subsequently, all the 3
lineages of hematopoiesis were suppressed with 65% by
plasma cell infiltration  (Figure).Strana 598 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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Fig. 3 í Centrifuged deposit of pleural fluid showed plenty
of plasmacytoid cells, including binucleated and
multinucleated ones admixed with a few reactive mesothelial
cells and macrophages (MGG, u200).
Therefore the final diagnosis was multiple myeloma
with myelomatous involvment of pleura.
Flat bones radiography, except degenerative changes to
pelvis, found no other pathologic changes.
On the account of technical reasons, it was not possible
to begin chemotherapy in accordance with the protocol for
plasmaproliferative disease so the patient was referred to the
competent regional hospital for further treatment. Three days
after the patient was transferred, his general condition wors-
ened in terms of his state of consciousness, which was up to
the level of somnolence, so that the prescribed therapy was
not administered.  On the seventh day after his transfer, res-
piratory arrest appeared which resulted in lethal outcome.
Discussion
In multiple myeloma, the bone marrow is infiltrated
with abnormal plasma cells leading to multifocal destructive
bone lesions. Clinical presentation of MM is seen in the ap-
pearance of general weakness, exhaustion, loss of weight,
pain in lumbar spine area, various degrees of renal failure,
anemic syndrome, and if also spread to the respiratory sys-
tem, there are symptoms in the upper part of the respiratory
tract, too 
1–9.
Myeloma cells found at extramedullary site may be be-
cause of EMP or due to extramedullar dissemination of mul-
tiple myeloma. EMP is an uncommon variant of MM, end it
manifests as solitary plasmocytoma. Solitary plasmocytomas
occur most commonly in the nasal cavities, paranasal si-
nuses, nasopharngs lymph nodes, lung, intestinal tract, with-
out bonemarrow involvement. This tipe of plasmocytoma is
responsive to local irradiation and has very good prognosis.
Intrapulmonary plasmocytoma is uncommon repre-
senting less than 5% of all EMP 
8. In the MM with pulmo-
nary localization there is plasma cells infiltration of the bone
marrow and  myeloma plasma cells in the lung mass 
9.
 Sev-
eral cases of extramedulary plasmocytoma with the involve-
ment of lung parenchyma were only described.
In the presented patient, renal failure was the first mani-
festation of MM, and later pulmonary simptomatology oc-
curred. Because of the infiltrative mass in the lung paren-
chyma, pulmonary examination was initiated. Computer to-
mography of the chest showed pleural effusion, but also the
tumorous mass paravertebrally bilaterally, while the con-
ducted MRI of the thoracolumbar spine showed no signifi-
cant changes on bone structures 
13–15. In the course of further
examination in order to do diagnostic puncture of pleural ef-
fusion, thoracocentesis was done, while cytological findings
of pleural punctuate showed numerous plasma cells. Concur-
rently, laboratory analysis of serum protein electrophoresis
showed M-peak in the gamma region 
12, 14, 16.
  The MM diag-
nosis was confirmed with biopsy of the bone marrow and the
results of more than 65% of plasma cells in myelogram.
Renal failure developed at the very beginning of the
disease, while the need for continuous hemodialysis proce-
dures as a sign of irreversible renal failure also corroborated
the gravity of the disease and shorter median survival of
these patients (on the average 4 months from the first symp-
toms of the disease).
Fig. 4 – Bone marrow examination revealed hypercellular marrow with depression of erythropoiesis and leukopoiesis and
adequate megakaryopoiesis, and a large number of plasma cells, above 65% of nucleated cell population, including binu-
cleate and multinucleate forms (MGG: left u 200; right u 400).Volumen 71, Broj 6 VOJNOSANITETSKI PREGLED Strana 599
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Dissemination of EMP in the lung is exceptionally rare,
and shows up in about 3% of a total number of patients diag-
nosed with MM 
11–13.
 Malignant pleural effusion combined
with pleural infiltration represents one of the late complica-
tions of the disease 
17.
 The appearance of pleural effusion is
an adverse prognostic indicator as well as the resistance to
the applied therapy, but also there are great chances for the
relapse of the disease despite conducting the radio-and/or
polychemotherapy. In some cases, regardless of the therapy,
it is also necessary to perform pleurodesis so as to improve
the general condition of the patient.
The literature lists the facts that very often, after the ap-
pearance of pleural effusion, even with the applied chemo-
therapy, there is a fatal outcome in the period of less than 4
months.
The presented patient had had the first symptoms of the
respiratory tract 3 months before the diagnosis of MM with
pulmonary localization was established. In that time, there
was a sudden worsening of respiratory symptomatology and
progression of pleural effusion so that chemotherapy could
not be applied, but the condition resulted in lethal outcome.
Conclusion
Extramedullary dissemination of multiple myeloma in
the lung is very uncommon and the prognosis of patients
with it is very poor, oppositely to patients with primary pul-
monary plasmocytoma to long survival rates. Multiple mye-
loma is a disease of aged population, with its severe clinical
prognosis, heterogeneous symptoms, and the diagnosis is dif-
ficult.
Because of that, in patients of middle and older age,
with general weakness, exhaustion, loss of weight, anemia,
and renal failure, if symptoms of respiratory tract occur, con-
sider this uncommon disease – multiple myeloma with lung
involvement.
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